Seeking Alpha

Michael Murphy's  Instablog

Michael Murphy grew up in Newark, Delaware, which a sign at the city limits proclaimed: “The Educatoinal Center of the State.” After graduating from the public schools he earned an A.B. cum laude from Harvard College and began working as a COBOL mainframe programmer on an IBM 1401 in the... More
My business:
New World Investor
My blog:
NewWordlInvestor.com
  • Buy The Obesity Drug Basket: ARNA, OREX, VVUS 12 comments
    Sep 20, 2009 06:22 AM | about stocks: ARNA, OREX, VVUS
    For many years, the Department of Agriculture has published a food triangle that recommends carbohydrates as the basis of a healthy diet, even though there is no minimum daily requirement for carbs. None. Dr. Atkins is rolling over in his grave.


    USDA Food Pyramid
    Although this has done far more damage to the populace than the management of Enron, Citigroup, AIG and Moody's combined, no one was ever fired.
     
    Then the FDA blessed high fructose corn syrup as a sugar replacement, over the strong objections of the soft drink industry that said the stuff was dangerous. Archer Daniels Midland has one of the largest political operations in Washington - why do you think our government is committed to corn-based ethanol? Americans now average 60 gallons of soft drinks a year and 40 pounds of high fructose corn syrup.
     
    The obesity resulting from these two humongous errors in judgment is a risk factor for diabetes, heart disease, cancer, osteoporosis and liver damage. Obesity is widely recognized as a public health epidemic, growing fastest in developing countries. The World Health Organization says 700 million adults will be obese in 2015, up from 400 million in 2005 - nearly a double in 10 years.
     
    According to the National Center for Health Statistics, 34% of American adults are obese with a body mass index of 30 or more, and another 32.7% are overweight with a body mass index of 25 to 29.9. For a 5'6” woman, an overweight body mass index of 25 equates to 155 pounds, and an obese body mass index of 30 equates to 186 pounds. For a 6' man, an overweight body mass index of 25 equates to 184 pounds, and an obese body mass index of 30 equates to 221 pounds. You can find the bad news for your height and weight at http://www.nhlbi.nih.gov/guidelines/obesity/bmi_tbl.htm.
     
    For every 2 ¼ inch increase in waist circumference, the chances of death rise by 17% for men and 13% for women. Obesity is serious stuff, responsible for at least 300,000 deaths a year in the U.S. alone.
     
    So a weight loss drug with a high benefit to risk ratio is a certain blockbuster. The U.S. market alone is estimated at $5 billion to $10 billion a year. But a winning drug has to be really effective and really safe. The only two FDA-approved anti-obesity prescription drugs currently on the market are Roche's Xenical and Abbott Laboratories' Meridia.
     
    Xenical was approved in 1999 and reduces the absorption of dietary fat into the bloodstream. Aside from the common side effects of gas with fecal discharge and fecal incontinence, Xenical blocks the absorption of beta-carotene and the fat soluble vitamins A, E, D, and K, so you have to take a multivitamin within two hours of taking Xenical. But the biggest problem is that it doesn't work very well, as it does nothing to reduce one's appetite and requires a reduced-calorie diet and an exercise regimen to lose weight. Patients just don't comply very well, possibly because gas with fecal discharge is not all that welcome in the weightlifting room.
    Meridia was approved in 1997, and it acts on brain chemicals to create a feeling of fullness, hopefully leading to reduced food intake. Unfortunately, reports of adverse reactions began piling up, and groups petitioned the FDA to recall the drug. The FDA refused to ban it, but they keep strengthening the label. It also doesn't work very well, because obese people usually keep eating for other reasons than they feel full.
     
    Although Meridia is still on the market, many others are not. Fen-phen, the combination drug of fenfluramine and phentermine from Wyeth, reached $6 billion in sales but then was banned in 1997 after fenfluramine was found to cause leaky heart valves, a serious heart condition.. Acomplia from Sanofi-Aventis was approved in the European Union in 2006. In June 2007, the FDA rejected Acomplia, saying that the drug's benefits did not outweigh its risks. It turned out to cause serious psychiatric disorders and was banned by the EU in 2008.
     
    With the fen-phen and Accomplia problems, Solvay Pharmaceuticals killed its Phase II obesity drug in late 2008, citing the current stringent regulatory environment. At the same time, Pfizer abandoned Otenabant, a late-stage antagonist of the cannabinoid type 1 receptor. Merck puled the plug on Taranabant last October, a Phase III program unfortunately of the same class as Accomplia. They cited unspecified side effects.
     
    So with the obesity docs desperate for better drugs, Arena Pharmaceuticals (ARNA), Orexigen Therapeutics (OREX) and Vivus (VVUS) are in a horse race to provide the next big winner. Amylin (AMLN) is in the early stages of trying a combination of leptin, which was a bust for Amgen (AMGN), and pramlintide, Amylin's approved drug for diabetes. They will not be a contender for many years, if ever.

    Arena reported its BLOOM Phase III data in the spring, and we just got the BLOSSOM Phase III data on September 18. Vivus recently reported good Phase III data and the stock rocketed higher. Orexigen reported their Phase III data in June. The table below compares what we know so far.


     
    Arena's lorcaserin is a new chemical entity, not tested in combination with anything else. Patients had very significant weight loss in the first year, and at the recent American Diabetes Association meeting, Arena showed that continued treatment with lorcaserin helped significantly more patients maintain their weight loss in the second year, as compared to those on placebo. The diet and exercise guidelines in Arena's Phase III trials were very minimal, so there was good patient compliance with only a 7% dropout rate due to adverse events. In general, there was a large subset of patients who saw rapid weight loss in the first four weeks, and those patients continued to be the best responders in the trial, losing far more weight than the average.
     
    Because lorcaserin is of the same family as the recalled fenfluramine, heart valve safety was a major issue in the BLOOM and BLOSSOM trials. The data from both trials added together clearly will convince the FDA that lorcaserin has no negative impact on heart health. Remarkably, both trials actually showed it improved heart health, so I feel confident cardiac impact is a non-issue.
     
    Finally, about 20% of the obesity docs surveyed by the company said they would prescribe lorcaserin with phentermine right from Day One. This should give a major boost to all the weight loss figures in the table above, and I expect LorPhen to quickly become the talk of the cocktail circuit and the most-requested regimen by patients. There is a critical mass point in the adoption of any new technology, where the S-curve really takes off, and it happens to be 20%. I expect the progress from 20% of the obesity doctors combining lorcaserin with phentermine to 80% ( the usual top of the S curve) doing so will take less than three years. It's also helpful that weight loss in the first four weeks is a very good indication that lorcaserin will work well for a particular patient. If it isn't working, the doctor can add phentermine for a while, and if that doesn't work they can move on to one of the other two drugs.
     
    Arena will file for approval for lorcaserin by the end of the year, and with few safety issues it probably will be first to market by a few weeks, towards the end of 2010.
     
    Orexigen's Contrave is a combination of two generic drugs, bupropion and naltrexone. Bupropion is an antidepressant formerly marketed as Wellbutrin. It is used for smoking cessation and, unlike many antidepressants, does not cause weight gain. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol and opioid dependence. Contrave's numbers are very close to Arena's, except for the safety issue. Wellbutrin had a number of well-known side effects, and these appear to be a problem in Contrave, with a 22% dropout rate, triple that of lorcaserin. However, even though the FDA might examine this issue very closely for label purposes, I still expect Contrave to receive approval. Orexigen will not file for approval until early in 2010, so they will be third to market.
     
    Doctors are very unlikely to combine phentermine with a combination drug like this until they have seen safety studies, so Contrave will have to stand on its own against lorcaserin plus phentermine. There have been questions about the pricing model and insurance reimbursement for a drug that is a combination of two widely available, cheap generics. While compounding pharmacists can easily make a combination of bupropion and naltrexone, I expect most doctors will prefer to prescribe Contrave and most insurers will pick up the tab.

    Vivus' Qnexa recently reported all its Phase III data. Like Arena, patients taking Qnexa also achieved significant improvements in cardiovascular and metabolic risk factors including blood pressure, lipid levels, and type 2 diabetes. Qnexa also is a combination of two generic drugs, phentermine plus 100 milligrams of topiramate. Phentermine we know. It is the leading diet drug today, but must be prescribed for intermittent use due to side effects.

    Topiramate is an anti-epileptic drug. Unfortunately, in its 200-milligram standard dosage form it has a long list of side effects and FDA warnings. Significant side effects include headache, numbness & tingling, upper respiratory tract infection, diarrhea, nausea, somnolence, anorexia, insomnia, memory problems and dizziness. The FDA has warned that topiramate can cause acute myopia and secondary angle closure glaucoma with blurred vision and eye pain. Another serious side-effect is the development of osteoporosis. Most anti-epileptic drugs have been associated with a statistically significant increase in suicidality.
    Qnexa includes about half the standard dosage of topiramate, 92 milligrams. With an 18% adverse effect dropout rate, the FDA will again review safety very closely. I am expecting some heated advisory panel discussions for both Contrave and Qnexa, in the latter case also focusing on dosing phentermine continuously instead of intermittently. Phentermine alone is very effective for weight loss, so it is not surprising that Qnexa posted great numbers. However, phentermine can only be used for short periods, to give the patient time to detox. But I think Vivus has collected enough data to show that Qnexa has a positive risk/reward profile, and the side effect issues can be dealt with on the label and in the package insert. So I do expect approval, although some weeks or a few months after lorcaserin, even though Vivus also will file by the end of this year.
    Vivus faces the same business model issues as Orexigen about how aggressively they can price a drug that is a combination of two widely available, cheap generics, insurance reimbursement and compounding pharmacists. However, like Contrave, I expect most doctors to simply prescribe Qnexa and most payers to reimburse it.
     
    Marketing

    I expect all three drugs to be approved., lorcaserin around next October, Qnexa by the end of 2010 and Contrave sometime in early 2011. Due to topiramate's well-known side effects, I think most obesity doctors will start with lorcaserin alone, while 20% of them will combine lorcaserin with phentermine right from the beginning. Patients that don't respond to lorcaserin can either be moved to lorcaserin plus intermittent phentermine, or moved on to Qnexa, with close monitoring of long-term side effects. When Contrave is approved, it should become the alternate choice after lorcaserin to Qnexa, again due to the side effects. Because people respond differently to drugs, doctors will have the luxury of being able to switch among the three drugs (four, counting LorPhen) until they find the one the patient tolerates best and still loses significant weight.
     
    Where the deep-pocket big pharmas have struck out again and again in developing an obesity drug, these three companies have all hit home runs. Any company that gets to market with a safe and effective weight-loss drug will reap huge profits. Due to its sweet spot profile on efficacy, safety and easy tolerability, plus being a new chemical entity and a single-agent drug, I expect Arena to eventually get about half the U.S. market for obesity drugs, especially as more and more doctors prescribe lorcaserin with phentermine. The other half will split roughly 25% to Qnexa, held down by caution over topiramate, and 25% to Contrave, held down by caution over bupropion.
    Half the market would mean roughly $3 billion in sales for Arena in three years, which at 25% a year discounts back to $1.9 billion today. Arena has about 122 million shares outstanding if everything was exercised, so that is $15.50 a share in sales. Because this is a new chemical entity, it will have high gross margins and should support a typical pharmaceutical valuation of 5X to 6X revenues, or $77.50 to $93, either in the public market or as an acquisition price. That is over 10 times higher than the current price.
     
    Orexigen also would have a blockbuster in Contrave if they got 25% of the market, or $1.5 billion in sales in three years. That discounts back to $950 million today. Orexigen has only 46.4 million shares outstanding, so discounted Contrave revenues are around $20.65 per share. Orexigen may not be able to get quite the gross margins that Arena does, but a valuation of 4X to 5X revenues, or $82 to $103 seems fair, again either in the public market or as an acquisition price. Again, that is 9 to 11 times higher than the current price.
    The situation with Vivus is no different. Qnexa should be the third blockbuster in the group, also bringing in $1.5 billion in three years. Vivus has about 80.2 million shares outstanding after their recent offering, so the $950 million present value of Qnexa revenues translates to $11.85 a share. Again using a 4X to 5X revenue valuation range to adjust for possibly lower gross margins, the stock is worth $47 to $59 a share. Not surprisingly, that also is dramatically higher than the current price, four to five times higher.
     
    It appears that Wall Street is so focused on the trees of which drug will “win” that they are missing the forest - three potentially huge winners that will revolutionize the treatment of a major worldwide health problem, all with their clinical risks behind them. Focus on the forest and buy a basket of all of them.   At the upcoming Obesity Society annual meeting in Washington, DC October 24 - 28, all three companies will present additional data.  I urge you to buy the stocks before that meeting.
    Disclosure: Long ARNA

    Themes: weight loss, diet drugs, obesity, lorcaserin, Contrave, Qnexa, biotech, healthcare Stocks: ARNA, OREX, VVUS
Back To Michael Murphy's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

This post has 12 comments:

  •  
    Great Article.
    Sep 20 11:20 AM | Link | Reply
  •  
    Agreed, very good article.
    Sep 20 11:46 AM | Link | Reply
  •  
    a
    Sep 20 04:09 PM | Link | Reply
  •  
    Very good info and article with explicit data and info. I'm sure Alan Fruadstine will discount it though. Everyone knows Alan.
    Sep 20 04:30 PM | Link | Reply
  •  
    Interesting article.

    However, with all due respect, the author has a fundamental flaw in his argument.
    Although he accepts that ARNA drug is not effective (only 3% weigh loss), yet he choses ARNA drug by assuming that doctors will do ARNA a big faivor and prescribe inefficient ARNA's drug together with phentermine.

    However, as a doctor, I don't see why any doctor would put their neck on the line and take a risk by prescribing a combination of drugs with were not approved by FDA in combination. If that was the case, then neither VVUS, no Orex would not need to do any trials at all, as both their drugs are combination of known drugs.

    Well, well, just 3% weight loss after whole one year (!) of taking ARNA drug. This is a laughable. For goodness sake, my own weight fluctuates 3% per day from empty stomach to after 2-3 good meals.

    I would go for VVUS, as 9-14% weight loss on VVUS drug is very impressive and its reasonably save.
    Sep 20 04:47 PM | Link | Reply
  •  
    Obviously not all users will only lose 3% as the data shows. Many people will lose considerably more weight. The effectiveness of all drugs is not the same for everyone and this is widely understood. In addition, most people will avoid and NOT follow though with strict diet and exercise regimens. Also, I suspect you're missing the importance of drug safety to the majority of potential users these days. I doubt there would be so much interest in Dendreon (DNDN) if this was not a major concern. I know all of my friends including myself have voiced concerns on this subject in recent years and are avoiding drugs for this reason. During my last physical my soon to retire family doctor told me he personally avoids most drugs for this same reason.


    On Sep 20 04:47 PM biomax2000 wrote:

    > Interesting article.
    >
    > However, with all due respect, the author has a fundamental flaw
    > in his argument.
    > Although he accepts that ARNA drug is not effective (only 3% weigh
    > loss), yet he choses ARNA drug by assuming that doctors will do ARNA
    > a big faivor and prescribe inefficient ARNA's drug together with
    > phentermine.
    >
    > However, as a doctor, I don't see why any doctor would put their
    > neck on the line and take a risk by prescribing a combination of
    > drugs with were not approved by FDA in combination. If that was the
    > case, then neither VVUS, no Orex would not need to do any trials
    > at all, as both their drugs are combination of known drugs.
    >
    > Well, well, just 3% weight loss after whole one year (!) of taking
    > ARNA drug. This is a laughable. For goodness sake, my own weight
    > fluctuates 3% per day from empty stomach to after 2-3 good meals.
    >
    >
    > I would go for VVUS, as 9-14% weight loss on VVUS drug is very impressive
    > and its reasonably save.
    Sep 20 08:15 PM | Link | Reply
  •  
    By Brian Orelli
    September 18, 2009

    I'm really not sure what management said that got investors so excited; the data is lackluster at best. Lorcaserin might be strong enough to get approved, but it still pales in comparison to efficacy data released by VIVUS (Nasdaq: VVUS) and Orexigen Therapeutics (Nasdaq: OREX).

    For instance, VIVUS' Qnexa resulted in weight loss of 11.0% and 10.4%, beating placebo by about 9 percentage points in two recently completed trials. Lorcaserin, on the other hand, resulted in a 5.9% reduction in body weight, a mere 3 or 4 percentage points better than placebo, depending on which patient group you look at. Comparing data across trials can be deceptive at best, but in this case I think we can call a qualitative winner.

    Sure, the drug is safe. It doesn't seem to have the heart problems that plagued Wyeth's (NYSE: WYE) fen-phen or the psychiatric problems that plagued drugs from sanofi-aventis (NYSE: SNY), Pfizer (NYSE: PFE), and Merck (NYSE: MRK). And management wants to argue that it'll be a first-line treatment for that reason alone.

    But I have a hard time seeing doctors rushing to get their patients on lorcaserin when there may be other drugs on the market by then that help people shed so many more pounds. If doctors are looking for a low-risk solution, they might be better off prescribing diet and exercise changes than trying to eke out an additional 6- to 8-pound loss for a 200-pound person on lorcaserin.

    There may be some smaller role for lorcaserin on the obesity market, just as there has been for other less-than-stellar diet drugs before it, but if you're looking for a blockbuster homerun, I'm not sure you'll find it in this Arena.
    Sep 20 09:12 PM | Link | Reply
  •  
    Looks you have an agenda to post here? Doesn't looks like you are speaking the fact ARNA drug only produce merely 3.1% and 2% weight loss in two years!

    Safe? If doctors are looking for a low-risk solution, they might be better off prescribing diet and exercise changes than trying to eke out an additional 6- to 8-pound loss for a 200-pound person on lorcaserin. LOL.

    I just checked your previous posts, looks you are always an ARNA pumper, and you kept bashing VVUS, although tried your best to make you looks like fair and objective. You need to wake up from your fantasy. Game over for ARNA, period.
    Sep 20 09:19 PM | Link | Reply
  •  
    BTW, did your DNDN reached $360/share now, mr. murphy? I can sell all shares to you for $180/share. LOL.
    Sep 20 09:30 PM | Link | Reply
  •  
    biomax2000 - the overall weight loss figures are 5.9% for lorcaserin, 6.1% for Contrave, and 10.6% for Qnexa. Don't be fooled by variations in the placebo response. Lorcaserin and Contrave were about equal, and Qnexa was better. Now look at adverse events - 7% for lorcaserin, 22% for Contrave, 18% for Qnexa. Now look at the diet and exercise regimen - essentially nothing for lorcaserin, and only a little bit more for Contrave. Much more for Qnexa.

    That's why all these drugs are winners. The elephant in the room is LorPhen. 20% of obesity doctors surveyed said they would prescribe lorcaserin plus phentermine from the beginning. Most of the other 80% said they would prescribe lorcaserin instead of phentermine. I'm sure they would be equally happy to prescribe Contrave or Qnexa instead of phentermine. In the real world, I expect doctors to switch patients among these four choices as needed to find that balance between weight loss (which includes patient compliance on the diet and exercise required) and side effects.

    Penn Bioinvestor - I like ARNA, OREX and VVUS, as the article says. They make a great basket to participate in a virtual revolution in obesity care. Oh, my target for DNDN is five years out, as stated.
    Sep 20 11:39 PM | Link | Reply
  •  
    I forgot to mention the forthcoming Obesity Society annual meeting in Washington, DC October 24 - 28. All three companies will present additional data there, and that is an excellent reason to buy the basket of stocks well before the meeting.
    Sep 21 12:17 AM | Link | Reply
  •  
    "there was good patient compliance with only a 7% dropout rate due to adverse events."

    If you talk about good patient compliance, you need to look at overall completion rate:

    Arena: BLOSSOM - The Week 52 completion rate was higher for patients on lorcaserin 10 mg twice daily (57.2%) and 10 mg once daily (59.0%) compared to patients on placebo (52.0%).

    Vivus: Completion rate for EQUIP was 47%, 57%, 59% for patients taking placebo, low-dose Qnexa and full-dose Qnexa, respectively; and Completion rates for CONQUER were 57%, 69%, 64% for patients taking placebo, mid-dose Qnexa, and full-dose Qnexa, respectively.

    Thus there is no advantage in this regard for Arena at all.

    If you talk about safety, then you can use dropout due to AE where Arena has a little advantage. Vivus's efficacy advantage is very dramatic.
    Sep 21 01:30 AM | Link | Reply
Full index of posts »
Latest Followers
Posts by Ticker
ARNA, BCRX, DNDN, OREX, QQQQ, SPX, SPY, VVUS

Latest Comments


Most Commented
  1. Buy The Obesity Drug Basket: ARNA, OREX, VVUS (12 Comments)
  2. Dendreon: A $360 Stock? Or Is That Too Low? (11 Comments)
  3. BioCryst's Korean Partner Gets Emergency Use Authorization (10 Comments)
  4. BioCryst's Japanese Partner Gets Priority Review (6 Comments)
  5. A Biotech Triple Play: Dendreon (DNDN) to BioCryst (BCRX) to Arena (ARNA) (4 Comments)
Posts by Themes
antiviral, antivirals, BioCryst, biotech, Biotech, biotechnology, cancer, CDC, coincident indicators, Contrave, diet drugs, Dow Jones, Economy, FDA, flu, Green Cross, H1N1, healthcare, HHS, ICU, influenza, lorcaserin, Market, Nasdaq, obesity, pandemic, peramivir, prostate cancer, Provenge, Qnexa, recession, recovery, Relenza, S P, Shionogi, stock market, swine flu, Tamiflu, weight loss
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.